GlassScriptPhysician profile
Alex Mirzoev
NPI 1780061234
$2,415.83
in general payments reported to CMS, 2019-2025
14 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $150 · 2022: $333 · 2023: $630 · 2024: $824 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $644.56 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $400.42 | 2019-2024 | |
| Genzyme Corporation | $310.22 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $127.86 | 2024 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $125.00 | 2019 | |
| Genentech USA, INC. | $120.55 | 2022 | |
| Horizon Therapeutics Plc | $120.13 | 2023 | Uplizna |
| Tg Therapeutics, INC. | $115.36 | 2024 | |
| Abbvie INC. | $112.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $111.02 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $85.92 | 2024 | Zeposia |
| Argenx US, INC. | $78.75 | 2022 | |
| Celgene Corporation | $41.95 | 2024 | Zeposia |
| Vanda Pharmaceuticals INC. | $22.09 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Mirzoev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.